Candel Therapeutics, Inc. (CADL) Stock Price & Analysis

Candel Therapeutics, Inc. (CADL) fell 1.47% to USD 12.78 as of September 8, 2026 at 05:49 UTC, according to Nexqual real-time market data.

CADL last closed at USD 12.78; the session ranged USD 12.76–13.05 on volume of 535,822 shares. Market capitalization is —, with a 52-week range of USD 4.35–14 (NGM). Source: Nexqual, September 8, 2026 at 05:49 UTC.

Key Statistics (as of September 8, 2026 at 05:49 UTC)

Technical Analysis (CADL)

Nexqual's technical model rates CADL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:49 UTC.

From Candel Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have also designed additional novel viral immunotherapy candidates using our proprietary enLIGHTEN™ Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
• The FDA granted Fast Track Designation for the use of aglatimagene for the treatment of localized, primary prostate cancer in combination with radiation therapy to improve the local control rate. o The primary goal of curative treatment for localized prostate cancer is complete tumor eradication, as outlined by National Comprehensive Cancer Network (NCCN) guidelines.
• Therefore, this study aimed to assess whether adding aglatimagene plus valacyclovir to standard of care (SoC) radiotherapy could improve disease-free survival (DFS) in patients pursuing curative treatment, a primary endpoint established in the SPA with the FDA.
• Key attributes of the enLIGHTEN™ Discovery Platform include: ▪ Strong focus on human biology, including deep phenotyping of human tumors, to increase probability of success ▪ Data driven selection of the payload.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:49 UTC. This page is informational and not investment advice.